Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Junctional Epidermolysis BullosaEpidermolysis Bullosa (EB)Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops)

ELK-003 eye drops are a standardized amniotic fluid secretome formulation. It contains essential extracellular matrix proteins, such as collagen type VII and laminin-332, which are critical for maintaining corneal integrity in EB patients. In addition, ELK-003 also includes growth factors that stimulate corneal healing and tissue regeneration. This combination of matrix proteins and growth factors aims to enhance corneal surface stability.

Trial Locations (1)

8580670

RECRUITING

Fundación DEBRA Chile, Niños Piel de Cristal, Santiago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Eliksa Therapeutics, Inc.

UNKNOWN

collaborator

Centro de la Vision

UNKNOWN

lead

Fundación DEBRA Chile, Niños Piel de Cristal

OTHER

NCT06713434 - Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa | Biotech Hunter | Biotech Hunter